Business
Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026
MONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, ...
About this update from Cannara Biotech, Inc.
[{"type":"text","content":"Cannara Achieves OTCQX Qualification and Announces Release of Fiscal Q1 2026 Financial Results on January 26, 2026\nMONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., is pleased to announce that it has qualified to have its common shares quoted for trading on the OTCQX Best Market (“OTCQX“). Cannara’s common shares were previously quoted on the OTCQB Venture Market. Effective today, Cannara’s common shares will begin trading on OTCQX under the symbol “LOVFF”. The Company’s common shares will continue to be listed on the TSX Venture Exchange as well as on the Frankfurt Stock Exchange, both of which remain unchanged and unaffected by the OTCQX qualification. OTCQX, the highest-level market of the OTC Markets in the United States, is designed for established, investor-focused U.S. and international companies. Trading on OTCQX is expected to enhance the company’s visibility and accessibility among U.S. investors. To qualify for OTCQX, companies must meet high financial reporting standards, follow best practices with respect to corporate governance, and demonstrate compliance with applicable securities laws. U.S. investors can access the Company’s current financial disclosures and real-time Level 2 quotes at www.otcmarkets.com. “Our qualification to trade on OTCQX is a meaningful step forward in Cannara’s capital markets strategy,” said Nicholas Sosiak, Chief Financial Officer of Cannara Biotech. “It increases our exposure to institutional and retail investors in the United States while reinforcing our commitment to strong governance, disclosure, and disciplined growth.” Q1 2026 FINANCIAL RESULTS The Company also announced it will release its financial results for the first quarter of fiscal 2026 on Monday, January 26, 2026, at 7:00 a.m. ET. Cannara Biotech CEO Zohar Krivorot and CFO Nicholas Sosiak will host an earnings webcast on January 26, 2026, at 11:00 a.m. ET, consisting of prepared remarks follow...